Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152103 | 0.82 | CYP2A6 (0.51) | CYP2A6TRPV1CNR2SLC22A12 | |
| SCHEMBL2477267 | 0.79 | TRPV1 (0.62) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL13834139 | 0.77 | CYP2A6 (0.63) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL64623 | 0.77 | CYP2A6 (0.68) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL32509667 | 0.77 | CYP2A6 (0.68) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL10094698 | 0.76 | TRPV1 (0.64) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL3975427 | 0.76 | CYP2A6 (0.56) | CYP2A6TRPV1CNR2METAP2NOS3 | |
| SCHEMBL3974637 | 0.76 | CYP2A6 (0.56) | CYP2A6TRPV1CNR2METAP2GRIA2 | |
| SCHEMBL7068186 | 0.76 | CYP2A6 (0.56) | CYP2A6TRPV1CNR2METAP2PDK1 | |
| SCHEMBL1259263 | 0.76 | CYP2A6 (0.56) | CYP2A6TRPV1CNR2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | CYP2A6 953/4885TRPV1 4454/4885CNR2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.